Oosthuizen Johannes Jacobus
SEC CIK 1916310 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co. | SVP, U.S. Market | 22.6K | — | $10.25M | 33 | 2022-05-01 | 2026-04-29 |
Most active insiders at MRK, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Zachary Jennifer | EVP, GC | — | $25.20M |
| 2 | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | — | $11.29M |
| 3 | Guindo Chirfi | EVP, Access, Policy, Comms | — | $8.15M |
| 4 | Williams David Michael | EVP, Chief Info, Digital Off | — | $8.13M |
| 5 | Davis Robert M | COB, CEO, Pres, Dir | — | $5.60M |
| 6 | Litchfield Caroline | EVP, CFO | — | $5.02M |
| 7 | Li Dean Y | Pres, Executive VP, MRL | — | $2.99M |
| 8 | Maraldo David R. | EVP, Pres. MMD | — | $2.41M |
| 9 | Oosthuizen Johannes Jacobus | Pres, U.S. Market | — | $1.83M |
| 10 | Smart Dalton E. III | SVP Fin. - Gbl Ctrl | — | $766.0K |
Transactions 33
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-01 17:34 | 2026-04-29 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | EVP, Oncology, Int?l | M - OptEx | $110.03 | +1,377 | 22.6K | +6% | +$151.5K |
| D | 2026-05-01 17:34 | 2026-04-29 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | EVP, Oncology, Int?l | F - Tax | $110.03 | -679 | 21.9K | -3% | -$74.7K |
| 2026-02-06 | 2026-02-06 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale | $121.87 | -15.0K | 21.2K | -41% | -$1.83M | |
| 2026-01-28 | 2026-01-26 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | A - Grant | $107.40 | +5,026 | 36.2K | +16% | +$539.8K | |
| 2025-02-20 | 2025-02-19 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale | $84.09 | -8,500 | 30.7K | -22% | -$714.8K | |
| D | 2025-02-11 | 2025-02-08 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | F - Tax | $87.28 | -6,404 | 39.2K | -14% | -$558.9K |
| D | 2025-02-11 | 2025-02-08 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $87.28 | +13.0K | 45.6K | +40% | +$1.13M |
| 2025-01-29 | 2025-01-27 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | A - Grant | $97.94 | +8,664 | 32.6K | +36% | +$848.6K | |
| D | 2024-05-06 | 2024-05-04 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | F - Tax | $127.51 | -450 | 23.8K | -2% | -$57.4K |
| D | 2024-05-06 | 2024-05-04 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $127.51 | +912 | 24.3K | +4% | +$116.3K |
| DM | 2024-02-05 | 2024-02-02 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $78.80 | +20.9K | 42.3K | +98% | +$1.65M |
| D | 2024-02-05 | 2024-02-02 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale+OE | $127.18 | -19.0K | 23.3K | -45% | -$2.41M |
| 2024-01-24 | 2024-01-22 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | A - Grant | $119.43 | +3,133 | 21.3K | +17% | +$374.2K | |
| 2023-11-13 | 2023-11-09 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale | $102.38 | -2,081 | 18.2K | -10% | -$213.1K | |
| D | 2023-10-31 | 2023-10-30 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | F - Tax | $102.82 | -451 | 20.3K | -2% | -$46.4K |
| D | 2023-10-31 | 2023-10-30 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $102.82 | +915 | 20.7K | +5% | +$94.1K |
| D | 2023-05-05 | 2023-05-04 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $118.22 | +907 | 20.2K | +5% | +$107.2K |
| D | 2023-05-05 | 2023-05-04 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | F - Tax | $118.22 | -447 | 19.8K | -2% | -$52.8K |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $115.47 | +866 | 19.7K | +5% | +$100.0K |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | F - Tax | $115.47 | -427 | 19.3K | -2% | -$49.3K |
| 2023-01-25 | 2023-01-23 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | A - Grant | $109.88 | +2,091 | 18.8K | +12% | +$229.8K | |
| 2022-11-10 | 2022-11-09 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale | $103.21 | -1,795 | 16.7K | -10% | -$185.3K | |
| DM | 2022-11-07 | 2022-11-07 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $0.00 | +52.7K | 43.5K | New | $0 |
| D | 2022-11-07 | 2022-11-07 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale+OE | $99.47 | -45.6K | 18.5K | -71% | -$4.53M |
| D | 2022-11-01 | 2022-10-28 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale+OE | $100.21 | -3,633 | 10.9K | -25% | -$364.1K |
| D | 2022-11-01 | 2022-10-30 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | F - Tax | $100.77 | -450 | 11.3K | -4% | -$45.3K |
| D | 2022-11-01 | 2022-10-30 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $100.77 | +913 | 11.8K | +8% | +$92.0K |
| D | 2022-05-05 | 2022-05-04 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | SVP, U.S. Market | M - OptEx | $87.10 | +907 | 15.0K | +6% | +$79.0K |
| D | 2022-05-05 | 2022-05-04 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | SVP, U.S. Market | F - Tax | $87.10 | -447 | 14.5K | -3% | -$38.9K |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | SVP, U.S. Market | F - Tax | $87.65 | -381 | 14.1K | -3% | -$33.4K |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | SVP, U.S. Market | M - OptEx | $87.65 | +773 | 14.4K | +6% | +$67.8K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | SVP, U.S. Market | F - Tax | $88.69 | -427 | 13.7K | -3% | -$37.9K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Oosthuizen Johannes Jacobus | SVP, U.S. Market | M - OptEx | $88.69 | +866 | 14.1K | +7% | +$76.8K |
Purchase Sale Sale after option exercise All abbreviations